Berotralstat for hereditary angioedema with C1 inhibitor deficiency: a practical guide for clinicians

Adil Adatia,Markus Magerl

DOI: https://doi.org/10.3389/fimmu.2024.1442671

IF: 7.3

2024-10-08

Frontiers in Immunology

Abstract:Hereditary angioedema due to C1 inhibitor deficiency (HAE-C1INH) is a rare congenital disorder that causes episodic swelling. Decreased or dysfunctional C1INH, the key inhibitor of the kinin-kallikrein system, leads to increased plasma kallikrein activity and the resultant excessive bradykinin causes angioedema(1).The morbidity and decreased quality of life of HAE-C1INH patients has motivated the increasing use of long-term prophylaxis (LTP) to prevent swelling attacks, when modern LTP agents became available a few years ago. The oral kallikrein antagonist berotralstat was approved in the United States and European Union in 2020 and 2021, respectively. The 2021 international HAE-C1INH guideline recommends berotralstat as a first-line therapy alongside plasma-derived C1 inhibitor (pd-C1INH) and lanadelumab(2).Herein, we present a practical guide to aid the clinician in the optimal use of berotralstat in HAE-C1INH based on available data and the experience at the Angioedema Centers of Reference and Excellence(3) in Berlin, Germany and Edmonton, Canada.Berotralstat is an oral small molecule that specifically inhibits plasma kallikrein. It is administered once daily at a dose of 150 mg. In the United States, a 110 mg dose is also available. It achieves a steady state plasma concentration in 6-12 days and has an elimination half-life of 93 hours(4). Administration with food does not impact the maximum serum concentration or total exposure of the medication(4).The efficacy of berotralstat was established in a double-blind, parallel-group study of 24 weeks duration(APEX-2). There were n=121 subjects randomized 1:1:1 to placebo, berotralstat 150 mg daily, or berotralstat 110 mg daily, and there was a 44% and 30% reduction in attack frequency/month in the treatment versus placebo arm at the 150 and 110 mg doses, respectively(5). The subsequent extension studies showed persistent and perhaps increased efficacy over time, with the 150 mg arm achieving a 79% reduction in attack frequency compared to baseline(6, 7) after 6 months (n=21). Real-world evidence studies have confirmed these results in various countries(8-10).Berotralstat was generally well tolerated at both doses. There was one severe adverse event (SAE)in the 110-mg berotralstat and three SAEs in the placebo arm, none of which were classified as drug related(5). The most frequent side effects observed in APEX-2 were gastrointestinal (GI) symptoms (e.g., abdominal discomfort, diarrhea). These were seen in 50% (20/40) of subjects receiving berotralstat 150 mg versus 36% (14/39) of subjects receiving placebo but tended to resolve over time. The GI symptoms can be mitigated by taking the medication with the largest meal of the day. Additionally, the graded introduction of berotralstat using the Berlin protocol, which involves starting with 1 tablet (150 mg) every third day and then increasing dosing frequency as tolerated to 1 tablet every other day and finally to 1 tablet daily, can improve tolerability (11). Some clinicians worry that GI upset may be misattributed to abdominal angioedema and result in inappropriate use of on-demand therapy. But, in our experience, patients (including those who have and have not had previous abdominal episodes) are generally able to differentiate between these when given anticipatory guidance. Before initiating therapy with berotralstat, patients must be informed about the possibility of gastrointestinal side effects, but care should be taken not to overemphasize this point in order to avoid nocebo effects. Additionally, headache was seen in 10.0% (4/40) of patients in the 150 mg arm of APEX-2 but also in 5.1% (2/39) of patients in the placebo arm. In our experience, it has not been a patient concern.QT interval prolongation was observed with berotralstat at doses 3-fold greater than that used clinically. At the approved dose of 150 mg daily berotralstat does not cause significant QT interval prolongation and electrocardiographic monitoring is not required. In APeX-2, one patient discontinued therapy due to elevated liver enzymes in the context of prior therapy with attenuated androgens. However, no regular laboratory monitoring is needed according to the drug monograph(4) and we have not observed elevated liver enzymes in our patients.Berotralstat is metabolized in the liver by CYP2D6 and CYP3A4 and hence may increase the plasma concentration of concomitant medications also metabolized by these enzymes (Table 1)(4). In some instances, reducing the dose of an interacting medication may be helpful. For example, one author has combined amlodipine with berotralstat and reduced the dose of the former (amlodipine 10 mg to 5 mg daily) without any loss of blood pressure control. Patients using a statin also metabolized by CYP3A4 (e.g., atorvastatin) can be switched to rosuvastatin, which is not a major CYP3A4 substrate (12) and thus does not interact with berotralstat. Given the poten -Abstract Truncated-

immunology